Drugs / FURESTEM-CD Inj.
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02000362 | Aug 2014 → Sep 2018 | Crohn disease | Kang Stem Biotech Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FURESTEM-CD Inj. | “Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)” NCT02000362 ↗ |
| Modality | Cell therapy | “Further, It has huge possibility as cell therapy products for autoimmune disease.” NCT02000362 ↗ |